Pyxis Oncology Reports Q3 2026 Results And Updates MICVO Development
Pyxis reported interim Phase 1 efficacy data for its head and neck cancer therapy Micvotabart pelidotin (MICVO) and reaffirmed plans for Phase 3 trial initiation in mid-2027, while updating cash runway guidance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed